Literature DB >> 4557072

Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.

M M Levine, H L Dupont, E J Gangarosa, R B Hornick, M J Snyder, J P Libonati, K Glaser, S B Formal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4557072     DOI： 10.1093/oxfordjournals.aje.a121431

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  10 in total

1.  Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally.

Authors:  M M Levine; T P Hughes; C R Young; S O'Donnell; J P Craig; H P Holley; E J Bergquist
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections.

Authors:  D Cohen; C Block; M S Green; G Lowell; I Ofek
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

5.  Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Authors:  K L Kotloff; F Noriega; G A Losonsky; M B Sztein; S S Wasserman; J P Nataro; M M Levine
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 6.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

7.  Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.

Authors:  L Van de Verg; D A Herrington; J R Murphy; S S Wasserman; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Authors:  K L Kotloff; F R Noriega; T Samandari; M B Sztein; G A Losonsky; J P Nataro; W D Picking; E M Barry; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.

Authors:  D Cohen; N Orr; G Robin; R Slepon; S Ashkenazi; I Ashkenazi; J Shemer
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

10.  Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

Authors:  F R Noriega; J Y Wang; G Losonsky; D R Maneval; D M Hone; M M Levine
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.